Literature DB >> 27677294

The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Takeo Nitta1, Toru Nakamura2, Tomoko Mitsuhashi3, Toshimichi Asano1, Keisuke Okamura1, Takahiro Tsuchikawa1, Eiji Tamoto1, Soichi Murakami1, Takehiro Noji1, Yo Kurashima1, Yuma Ebihara1, Yoshitsugu Nakanishi1, Toshiaki Shichinohe1, Satoshi Hirano1.   

Abstract

PURPOSE: The tumor-node-metastasis (TNM) classification defines R1 as the presence of tumor cells at the resection margin, while the current Royal College of Pathologists guidelines for pancreaticoduodenectomy specimens regard the presence of tumor cells within 1 mm from the resection margin as R1 (the "1-mm rule"). The aims of this study were to investigate the resection margin status of pancreatic head cancer retrospectively according to both the TNM and 1-mm rule classifications, and to evaluate the postoperative survival and tumor recurrence patterns.
METHODS: A total of 117 patients with pancreatic head cancer were the subjects of this study.
RESULTS: R11-mm rule resection was associated with a significantly worse disease-free survival (DFS) than R01-mm rule resection (p = 0.0259), while R1TNM had no impact on DFS. R11-mm rule resection margin status correlated with the incidence of tumor recurrence in the liver (p = 0.0483). In a multivariate analysis, R11-mm rule resection was the independent variable for predicting poor DFS (hazard ratio 1.71; p = 0.0289).
CONCLUSIONS: R1 resection margin status determined by the 1-mm rule may be an independent indicator for predicting disease recurrence, especially liver metastasis. These results may be useful for selecting the appropriate adjuvant therapy protocol and conducting strict surveillance in PDAC patients.

Entities:  

Keywords:  1-mm rule; Disease-free survival; Margin; Pancreatic ductal adenocarcinoma; TNM

Mesh:

Year:  2016        PMID: 27677294     DOI: 10.1007/s00595-016-1420-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  21 in total

1.  Most pancreatic cancer resections are R1 resections.

Authors:  Irene Esposito; Jörg Kleeff; Frank Bergmann; Caroline Reiser; Esther Herpel; Helmut Friess; Peter Schirmacher; Markus W Büchler
Journal:  Ann Surg Oncol       Date:  2008-03-20       Impact factor: 5.344

2.  Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer.

Authors:  Teiichi Sugiura; Katsuhiko Uesaka; Kisho Mihara; Keiko Sasaki; Hideyuki Kanemoto; Takashi Mizuno; Yukiyasu Okamura
Journal:  Surgery       Date:  2013-08-22       Impact factor: 3.982

3.  Redefining the R1 resection in pancreatic cancer.

Authors:  C S Verbeke; D Leitch; K V Menon; M J McMahon; P J Guillou; A Anthoney
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

4.  R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use.

Authors:  Bettina M Rau; Katharina Moritz; Sarah Schuschan; Guido Alsfasser; Friedrich Prall; Ernst Klar
Journal:  Surgery       Date:  2012-07-03       Impact factor: 3.982

5.  Can the new RCP R0/R1 classification predict the clinical outcome in ductal adenocarcinoma of the pancreatic head?

Authors:  M S Janot; S Kersting; O Belyaev; A Matuschek; A M Chromik; D Suelberg; W Uhl; A Tannapfel; U Bergmann
Journal:  Langenbecks Arch Surg       Date:  2012-06-14       Impact factor: 3.445

Review 6.  Resection margins in modern rectal cancer surgery.

Authors:  Nir Wasserberg; Haim Gutman
Journal:  J Surg Oncol       Date:  2008-12-15       Impact factor: 3.454

7.  Pancreaticoduodenectomy: a 20-year experience in 516 patients.

Authors:  C Max Schmidt; Emilie S Powell; Constantin T Yiannoutsos; Thomas J Howard; Eric A Wiebke; Chad A Wiesenauer; Joel A Baumgardner; Oscar W Cummings; Lewis E Jacobson; Thomas A Broadie; David F Canal; Robert J Goulet; Eardie A Curie; Higinia Cardenes; John M Watkins; Patrick J Loehrer; Keith D Lillemoe; James A Madura
Journal:  Arch Surg       Date:  2004-07

8.  Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Authors:  Ioannis T Konstantinidis; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers; David P Ryan; Jennifer A Wargo; Keith D Lillemoe; Cristina R Ferrone
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

9.  Favourable prognostic factors in a large UK experience of adenocarcinoma of the head of the pancreas and periampullary region.

Authors:  N P Jarufe; C Coldham; A D Mayer; D F Mirza; J A C Buckels; S R Bramhall
Journal:  Dig Surg       Date:  2004-06-24       Impact factor: 2.588

10.  Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin.

Authors:  Fiona Campbell; Richard A Smith; Philip Whelan; Robert Sutton; Michael Raraty; John P Neoptolemos; Paula Ghaneh
Journal:  Histopathology       Date:  2009-09       Impact factor: 5.087

View more
  11 in total

1.  Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.

Authors:  Asmita Chopra; Mazen Zenati; Melissa E Hogg; Herbert J Zeh; David L Bartlett; Nathan Bahary; Amer H Zureikat; Joal D Beane
Journal:  Ann Surg Oncol       Date:  2021-05-23       Impact factor: 5.344

2.  Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.

Authors:  Kim C Honselmann; Ilaria Pergolini; Carlos Fernandez-Del Castillo; Vikram Deshpande; David Ting; Martin S Taylor; Louisa Bolm; Motaz Qadan; Ulrich Wellner; Marta Sandini; Dirk Bausch; Andrew L Warshaw; Keith D Lillemoe; Tobias Keck; Cristina R Ferrone
Journal:  Ann Surg       Date:  2019-01-18       Impact factor: 12.969

3.  Can laboratory x-ray virtual histology provide intraoperative 3D tumor resection margin assessment?

Authors:  William Twengström; Carlos F Moro; Jenny Romell; Jakob C Larsson; Ernesto Sparrelid; Mikael Björnstedt; Hans M Hertz
Journal:  J Med Imaging (Bellingham)       Date:  2022-02-07

4.  Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cross-specialty Survey From the Pancreatobiliary Pathology Society Grossing Working Group.

Authors:  Deepti Dhall; Jiaqi Shi; Daniela S Allende; Kee-Taek Jang; Olca Basturk; Volkan Adsay; Grace E Kim
Journal:  Am J Surg Pathol       Date:  2021-10-01       Impact factor: 6.298

5.  Two cases of resectable pancreatic cancer diagnosed by open surgical biopsy after endoscopic ultrasound fine-needle aspiration failed to yield diagnosis: case reports.

Authors:  Reishi Toshiyama; Takehiro Noda; Hidetoshi Eguchi; Yoshifumi Iwagami; Daisaku Yamada; Tadafumi Asaoka; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Yutaka Takeda; Masahiro Tanemura; Eiichi Morii; Koji Umeshita; Masaki Mori; Yuichiro Doki
Journal:  Surg Case Rep       Date:  2017-02-25

6.  Whipple Grossing in the Era of New Staging: Should We Standardize?

Authors:  Jiaqi Shi; Olca Basturk
Journal:  Diagnostics (Basel)       Date:  2019-09-29

7.  Impact of resection margins on long-term survival after pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Cheng-Gang Li; Zhi-Peng Zhou; Xiang-Long Tan; Yuan-Xing Gao; Zi-Zheng Wang; Qu Liu; Zhi-Ming Zhao
Journal:  World J Clin Cases       Date:  2019-12-26       Impact factor: 1.337

8.  Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis.

Authors:  Carl Stephan Leonhardt; Willem Niesen; Eva Kalkum; Rosa Klotz; Thomas Hank; Markus Wolfgang Büchler; Oliver Strobel; Pascal Probst
Journal:  BJS Open       Date:  2022-03-08

9.  Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.

Authors:  Kim C Honselmann; Ilaria Pergolini; Carlos Fernandez-Del Castillo; Vikram Deshpande; David Ting; Martin S Taylor; Louisa Bolm; Motaz Qadan; Ulrich Wellner; Marta Sandini; Dirk Bausch; Andrew L Warshaw; Keith D Lillemoe; Tobias Keck; Cristina R Ferrone
Journal:  Ann Surg       Date:  2020-08       Impact factor: 13.787

10.  Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model.

Authors:  Thinzar M Lwin; Kentaro Miyake; Takashi Murakami; Jonathan C DeLong; Siamak Amirfakhri; Filemoni Filemoni; Sang Nam Yoon; Paul J Yazaki; John E Shivley; Brian Datnow; Bryan M Clary; Robert M Hoffman; Michael Bouvet
Journal:  Oncotarget       Date:  2018-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.